造血干细胞移植在复发难治霍奇金淋巴瘤中的若干问题

摘要

对于复发难治性霍奇金淋巴瘤，目前标准的治疗方案为解救化疗有效后给予大剂量化疗+自体干细胞移植（HDCT/ASCT）。常用的解救方案之间没有优劣，如BEAM，CBV，IGEV等。解救化疗后行PET检查对自体造血干细胞移植有重要的预后价值。降低预处理强度的异基因造血干细胞移植（RIC-alloSCT）可作为ASCT后复发患者一种有效的治疗方法。本文就造血干细胞移植在复发难治性霍奇金淋巴瘤中的若干问题进行综述。%The standard therapy for relapsed/refractory Hodgkin lymphoma (RR-HL) consists of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT). Salvage therapy is not obviously superior to commonly used regimens such as BEAM, CBV, and IGEV. Functional imaging with 18F-fluoro-2-deoxy-D-glucose positron emission tomogra-phy scanning is a critical predictor of the outcome after the completion of salvage chemotherapy and before ASCT. Meanwhile, re-duced-intensity conditioning allogeneic stem cell transplantation may induce a strong response in some patients with relapsing or pro-gressing HL after ASCT. In this study, we reviewed some problems in hematopoietic stem cell transplantation for treating RR-HL.